Small-molecule and function-blocking antibody approaches against single family members, LOX15,16 and LOXL2 (refs. 17,18) have been used with some success in various in vitro and in vivo cancer models17,19 yet have yielded limited success during translation into phase 2 clinical trials, likely a result of the critical involvement of other lysyl oxidase family members, suggesting that a pan-lysyl oxidase inhibitor may be more therapeutically effective. Here, LOX is linked to cancer.